In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies

Nuclear Medicine and Biology

Volumn 37, Issue 8, 2010, Pages 957-964

  Huhtala, Tuulia ^a   Laakkonen, Pirjo ^a,b   Sallinen, Hanna ^a   Ylä Herttuala, Seppo ^a   Närvänen, Ale ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Angiogenesis; Imaging; Lymph node; Monoclonal antibody; Ovarian carcinoma; SPECT CT

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F4 31C1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXILLARY LYMPH NODE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG LYMPH LEVEL; DRUG TUMOR LEVEL; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDIUM RADIOISOTOPES; INJECTIONS; LYMPH NODES; MICE; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 78049456673     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.03.001     Document Type: Article

References (21)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
2. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001, 7:192-198.
3. Alitalo K., Tammela T., Petrova T.V. Lymphangiogenesis in development and human disease. Nature 2005, 438:946-953.
4. Petrova T.V., Bono P., Holnthoner W., Chesnes J., Pytowski B., Sihto H., et al. VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors. Cancer Cell 2008, 13:554-556.
5. Tammela T., Zarkada G., Wallgard E., Murtomaki A., Suchting S., Wirzenius M., et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008, 454:656-660.
6. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
7. Psyrri A., Kassar M., Yu Z., Bamias A., Weinberger P.M., Markakis S., et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 2005, 11:8637-8643.
8. Cowden Dahl K.D., Zeineldin R., Hudson L.G. PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol Cancer Res 2007, 5:413-421.
9. Pytowski B., Goldman J., Persaud K., Wu Y., Witte L., Hicklin D.J., et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst 2005, 97:14-21.
10. Laakkonen P., Waltari M., Holopainen T., Takahashi T., Pytowski B., Steiner P., et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res 2007, 67:593-599.
11. Secord A.A., Blessing J.A., Armstrong D.K., Rodgers W.H., Miner Z., Barnes M.N., et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol 2008, 108:493-499. Gynecologic Oncology Group.
12. Wu A.M., Olafsen T. Antibodies for molecular imaging of cancer. Cancer J 2008, 14:191-197.
13. 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009, 50:123-131.
14. Raty J.K., Liimatainen T., Huhtala T., Kaikkonen M.U., Airenne K.J., Hakumaki J.M., et al. SPECT/CT imaging of baculovirus biodistribution in rat. Gene Ther 2007, 14:930-938.
15. Sallinen H., Anttila M., Narvainen J., Orden M.R., Ropponen K., Kosma V.M., et al. A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up. Gynecol Oncol 2006, 103:315-320.
16. Schindlbeck C., Hantschmann P., Zerzer M., Jahns B., Rjosk D., Janni W., et al. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow. Int J Gynecol Cancer 2007, 17:1047-1055.
17. Burton J.B., Priceman S.J., Sung J.L., Brakenhielm E., An D.S., Pytowski B., et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res 2008, 68:7828-7837.
18. Kohler M., Janz I., Wintzer H.O., Wagner E., Bauknecht T. The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res 1989, 9:1537-1547.
19. Bull Phelps S.L., Schorge J.O., Peyton M.J., Shigematsu H., Xiang L.L., Miller D.S., et al. Implications of EGFR inhibition in ovarian cancer cell proliferation. Gynecol Oncol 2008, 109:411-417.
20. Wen X., Wu Q.P., Ke S., Ellis L., Charnsangavej C., Delpassand A.S., et al. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225. J Nucl Med 2001, 42:1530-1537.
21. Ji R.C. Lymph node lymphangiogenesis: a new concept for modulating tumor metastasis and inflammatory process. Histol Histopathol 2009, 24:377-384.